Pitch Introduction
Mirai Clinical’s Japanese persimmon-based soap targets a specific age-related body odor issue that many people over 40 experience. Founder Koko Hayashi returned to Shark Tank seeking investment for her innovative beauty solution.
Business Overview
Mirai Clinical offers a line of Japanese persimmon-based body care products designed to eliminate Nonenal, a specific type of age-related body odor often referred to as “old man smell.” The company addresses the gap in traditional deodorizing products that only target generic body odors, not this specific age-related issue. Their target market consists of men and women over 40 who want to maintain a fresh, youthful scent. The unique selling proposition is their specialized formula using Japanese persimmon extract, which contains high tannin content that effectively neutralizes Nonenal odor.
| Company Detail | Information |
|---|---|
| Company Name | Mirai Clinical |
| Industry | Beauty/Fashion |
| Location | Los Angeles, CA |
| Founder | Koko Hayashi |
| Product Type | Persimmon-based body care |
About Founder’s
Koko Hayashi is a serial entrepreneur who previously appeared on Shark Tank Season 11 with her Face Yoga business. Her experience in Japan led her to discover the traditional use of persimmons for eliminating age-related body odors. This discovery inspired her to create Mirai Clinical, combining traditional Japanese knowledge with modern beauty science.
- Previously pitched Face Yoga on Shark Tank Season 11
- Discovered persimmon solution during work in Japan
- Created specialized product for age-related body odor
- Built company to $8.7 million in lifetime sales
Shark’s and Founder’s QnA
What is old man smell?
It’s a specific type of body odor called Nonenal that people over 40 start to produce. Regular soaps don’t eliminate this particular odor, but Japanese persimmon extract does due to its high tannin content.
How does persimmon eliminate this odor?
Persimmons have a high tannin content which chemically neutralizes Nonenal odor. The tannins absorb the body oils that create this specific smell.
What products do you offer?
We have a complete line including soap bars, body wash, body wipes, and deodorizing deodorant sticks, all formulated with persimmon extract.
What are your sales figures?
I have $8.7 million in lifetime sales. Last year we did $2.2 million with $250,000 in net profit.
What about this year’s sales projection?
This year we could have made $4 million if we hadn’t had a body wash shipment stolen. The case is currently under FBI investigation.
How are you selling these products?
We sell 100% online through our website and Amazon. We spend 30% of our income on Facebook ads.
Why wouldn’t regular deodorant soap work?
American deodorizing soaps target generic body odors, but not Nonenal. There are various kinds of body odors, and Americans test only generic types, not this specific age-related odor.
Do you have proof this works?
Yes, we have a partnership with a PMI lab in Japan that conducts all necessary testing to prove effectiveness.
What does it cost to make your products?
Our hero soap bar, which makes up 53% of sales, costs $1.85 to produce including shipping from Japan. It retails for $17.97.
What is your ROAS?
We have a blended ROAS of 2.5 on Amazon and other channels.
What is your $10 million valuation based on?
The market is underserved, baby boomers are aging, and we’re positioned to capture this growing demographic. Japan is a super-aged country and America is following the same trend.
Key Stats & Financials
Mirai Clinical demonstrated strong financial performance with significant lifetime sales despite facing operational challenges. The company showed promising margins and continued growth potential in an expanding market segment.
- Sales: $8.7 million lifetime sales, $2.2 million in 2023
- Margins: 53% hero product costs $1.85 to make, sells for $17.97
- Valuation: $10 million requested valuation
- Investment Request: $500,000 for 5% equity
- Use of Funds: Not specified in detail during pitch
| Financial Metric | Amount |
|---|---|
| Lifetime Sales | $8.7 million |
| 2023 Revenue | $2.2 million |
| 2023 Net Profit | $250,000 |
| 2024 Projected Sales | $4 million (before theft) |
| Hero Product Cost | $1.85 |
| Hero Product Retail | $17.97 |
Business Potential and TAM
The business potential for Mirai Clinical is significant given the aging population in the United States. As baby boomers continue to age, the target market for age-specific body care solutions will continue to expand. The company identified an underserved market opportunity with limited competition.
- Aging US population creates expanding target market
- Underserved market with limited competition
- Japan’s experience indicates future US trends
- Specific problem with dedicated solution
Mirai: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Age Group | 40 years and older |
| Gender | Both men and women |
| Geographic Focus | United States market |
| Income Level | Middle to upper-middle class |
| Shopping Behavior | Online shoppers, Amazon users |
Marketing and Distribution Strategy
Mirai Clinical’s marketing and distribution strategy focuses heavily on digital channels and direct-to-consumer sales. The company leverages online platforms to reach their target demographic effectively.
- 100% online sales through company website and Amazon
- 30% of income spent on Facebook advertising
- ROAS of 2.5 across all marketing channels
- Partnership with Japanese testing laboratories for credibility
Mirai Clinical Deal Outcome
Despite showing strong financial performance and a unique product solution, Mirai Clinical left the Shark Tank pitch without securing any investment deals. The sharks were unconvinced about the market size and necessity of the product.
| Shark | Decision |
|---|---|
| Kevin O’Leary | Out – Numbers too crazy, couldn’t justify valuation |
| Barbara Corcoran | Out – Didn’t believe the problem was widespread enough |
| Lori Greiner | Out – Didn’t see sufficient market need |
| Robert Herjavec | Out – Questioned whether this was even a real problem |
| Mark Cuban | Out – Concept was fun but not a serious business investment |
Mirai Clinical Post-Show Update
The company continued to grow after appearing on Shark Tank, with $3 million in annual revenue reported for 2024. With increased exposure from the show, they set a goal to double that revenue to $6 million in 2025.
Business Analysis & Lessons
Mirai Clinical’s pitch demonstrates several important business lessons about market validation and investment readiness. The company showed strong operational performance but faced challenges in convincing investors about market size and necessity. This highlights the importance of demonstrating not just that a product works, but that there is sufficient market demand to justify the requested valuation.
The case also demonstrates that having strong financials doesn’t automatically translate to investment interest. The sharks were looking for evidence that the problem being solved was significant enough to support the requested valuation and growth projections.
- Strong financials alone don’t guarantee investment success
- Market validation is crucial for niche product categories
- Valuation must align with demonstrated market potential
- Investors need to believe in the problem’s significance
Pitch Conclusion
Mirai Clinical’s Shark Tank pitch showcased a unique product addressing a specific market need with strong financial performance. While the company didn’t secure investment, it demonstrated resilience by continuing to grow post-show. What are your thoughts on niche beauty products like this? Share your perspective in the comments below.